Marshall Wace, LLP Arcus Biosciences, Inc. Transaction History

Marshall Wace, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $135,693 - $245,970	-6,888 Reduced 38.73%	10,896 $225,000
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $4.89 Million - $6.33 Million	-210,463 Reduced 92.21%	17,784 $466,000
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $856,020 - $1.87 Million	49,682 Added 27.82%	228,247 $5.78 Million
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $5.16 Million - $7.47 Million	178,565 New	178,565 $5.64 Million
Q2 2021 Aug 13, 2021	SELL	$22.75 - $35.77 $3.12 Million - $4.91 Million	-137,283 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $689,656 - $1.09 Million	-26,363 Reduced 16.11%	137,283 $3.86 Million
Q4 2020 Feb 16, 2021	BUY	$17.0 - $32.36 $2.78 Million - $5.3 Million	163,646 New	163,646 $4.25 Million
Q2 2020 Aug 13, 2020	SELL	$13.97 - $36.56 $35,609 - $93,191	-2,549 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$8.78 - $19.28 $22,380 - $49,144	2,549 New	2,549 $35,000
Q1 2019 May 14, 2019	SELL	$8.95 - $12.49 $206,431 - $288,081	-23,065 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$9.74 - $14.5 $52,031 - $77,459	5,342 Added 30.14%	23,065 $249,000
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.95 $192,826 - $264,958	17,723 New	17,723 $247,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.